Zhifei Longcom's Rabies Vaccine Achieves Non-Inferiority in Landmark Phase III Trial

What is the Impact of Zhifei Longcom’s New Rabies Vaccine?

Zhifei Longcom's new rabies vaccine demonstrates non-inferiority in Phase III trial, potentially expanding China's limited HDCV market currently dominated by just two manufacturers. The MRC-5 cell-based vaccine showed comparable immunogenicity and safety to the established Kanghua HDCV in both 5-dose Essen and 4-dose Zagreb regimens among participants aged 10-60 years.

How Was the Clinical Trial Designed and Executed?

The randomized, double-masked non-inferiority trial conducted at Hunan Provincial Center for Disease Control and Prevention has successfully demonstrated that the investigational freeze-dried human rabies vaccine developed by Anhui Zhifei Longcom Biopharmaceutical meets critical efficacy and safety benchmarks. The study enrolled 1,800 participants in the main phase, following an initial safety assessment in 79 subjects. Participants were randomized to receive either the investigational vaccine in a 5-dose Essen regimen, a 4-dose Zagreb regimen, or the control Kanghua vaccine in a 5-dose regimen.

Immunogenicity results were particularly encouraging, with the investigational vaccine achieving 100% seroconversion rates across all groups by day 14 after the first dose. Geometric mean concentration (GMC) of neutralizing antibodies showed the investigational vaccine was non-inferior to the control, with GMC ratios well above the pre-specified non-inferiority margin of 0.67. The 4-dose Zagreb group demonstrated a more rapid antibody response after the first dose compared to other groups, suggesting potential advantages of the two-dose initial series. "The non-inferiority of the 4-dose schedule to the 5-dose schedule was clearly established, which could offer practical benefits in clinical practice," noted the investigators in their assessment of the findings.

Immune persistence data showed that at three months post-vaccination, seropositivity rates remained high across all groups: 98.26% for the Essen group, 97.36% for the control group, and 98.42% for the Zagreb group. By 12 months, the rates remained robust at 88.45% and 88.35% for the 5-dose and 4-dose experimental groups, respectively, with no significant differences between regimens. This sustained immunogenicity profile suggests durable protection, a critical factor for public health officials evaluating new vaccine options.

Safety profiles were favorable across all treatment arms. In the main study phase, adverse events occurred in 35.17% of the Essen group, 36.50% of the control group, and 30.00% of the Zagreb group. The majority of adverse reactions were mild (Grade 1), with injection site pain being the most commonly reported local reaction. Grade 3 or higher adverse events were rare, occurring in only 1.17%, 0.50%, and 1.17% of participants respectively. Notably, the 4-dose Zagreb group showed a significantly lower incidence of adverse events compared to the control group (p=0.0198), potentially reflecting the benefit of fewer total injections.

Could This Vaccine Redefine China’s Rabies Market?

The study addresses a critical gap in the Chinese vaccine market, where human diploid cell vaccines (HDCVs) – considered the gold standard by the WHO since 1974 – are supplied by only two manufacturers: Chengdu Kanghua and Beijing Minhai. HDCVs offer advantages including absence of tumorigenic DNA risks and exogenous protein allergens, but their complex production process and high costs have limited widespread use in developing countries. According to WHO estimates, approximately 35,000-50,000 people die from rabies annually, with the vast majority occurring in rural areas of Africa and Asia, underscoring the urgent need for accessible and effective rabies vaccines.

Dr. Feng Li, lead investigator from Hunan Provincial CDC, commented, "These findings represent a significant step forward in expanding access to high-quality rabies prophylaxis in China. The comparable immunogenicity and favorable safety profile of the investigational vaccine in both dosing regimens provide flexibility for implementation across different healthcare settings."

The trial utilized the Rapid Fluorescence Focus Inhibition Test (RFFIT) for antibody quantification, with seropositivity defined as achieving a neutralizing antibody concentration ≥0.5 IU/mL per WHO immunological criteria. This methodology aligns with international standards for rabies vaccine evaluation. The study design included rigorous safety monitoring protocols, with systematic documentation of adverse events through immediate surveillance and active solicitation during follow-up periods.

What Do Future Perspectives and Challenges Entail?

While the trial provides robust evidence for the 10-60 age group, the investigators acknowledged limitations, including the absence of data for children and elderly populations, and the predominance of Han ethnicity among participants. Future studies would need to address these gaps to establish broader applicability across diverse populations. Additionally, the company has indicated plans to conduct post-marketing surveillance studies to gather real-world effectiveness data once the vaccine receives regulatory approval.

Industry Context: This successful Phase III trial comes at a time when global health authorities are emphasizing the need for expanded access to high-quality rabies vaccines, particularly in endemic regions. With rabies continuing to be a significant public health threat in many developing countries, there remains a substantial unmet need for cost-effective prophylactic solutions. Zhifei Longcom's MRC-5 cell-based vaccine could potentially increase competition in the HDCV market segment, potentially improving availability and affordability while maintaining the quality standards associated with human diploid cell platforms. The positive results for both dosing regimens also provide flexibility for implementation in different healthcare settings, aligning with global trends toward optimized vaccination schedules that maintain efficacy while improving resource utilization. As China continues to strengthen its biopharmaceutical sector, this development represents another step in the country's growing influence in the global vaccine market.

Summary

Zhifei Longcom's investigational freeze-dried human rabies vaccine has successfully completed a Phase III clinical trial, demonstrating non-inferiority to the established Kanghua vaccine in both immunogenicity and safety profiles. The randomized, double-masked study enrolled 1,800 participants aged 10-60 years at the Hunan Provincial Center for Disease Control and Prevention, comparing the investigational MRC-5 cell-based vaccine administered in 5-dose Essen and 4-dose Zagreb regimens against the control vaccine. Results showed 100% seroconversion rates by day 14 across all groups, with geometric mean concentrations of neutralizing antibodies exceeding the pre-specified non-inferiority margin. Immune persistence remained robust at 12 months, with seropositivity rates of approximately 88% in both experimental groups. The safety profile was favorable, with most adverse events classified as mild, and the 4-dose Zagreb regimen showing a significantly lower incidence of adverse events compared to the control group. This development addresses a critical gap in China's human diploid cell vaccine market, currently served by only two manufacturers, and could expand access to high-quality rabies prophylaxis. The trial utilized WHO-standardized methodology and demonstrated that both dosing regimens provide flexible implementation options for different healthcare settings. While the study focused on the 10-60 age group and predominantly Han ethnicity participants, the company plans post-marketing surveillance to gather real-world effectiveness data following regulatory approval.